Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify in Parkinson's Disease Psychosis
NCT00095810Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2003
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in Psychosis Associated With Parkinson's Disease (PDP), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Tolerability at 6 weeks. Started Jul 2003; status: completed.
02
Drugs
aripiprazole
03
Conditions
Psychosis Associated With Parkinson's Disease (PDP)
Beyond the preview
Go deeper on NCT00095810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095810.